The ability of animal studies to detect serious post marketing adverse events is limited-Reference-Cited by-同舟云学术

The ability of animal studies to detect serious post marketing adverse events is limited

Published:2012-12 Issue:3 Volume:64 Page:345-349
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

van Meer Peter J.K.,Kooijman Marlous,Gispen-de Wied Christine C.,Moors Ellen H.M.,Schellekens Huub

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference23 articles.

1. Committee for Medicinal Products for Human Use (CHMP), 2005. Guideline on Risk Management Systems for Medicinal Products for Human Use, London.

2. European Medicines Agency (online). Available from URL: (accessed 30.07.2012).

3. EU Parliament, 2004. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 Amending Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use.

4. Drug safety tests and subsequent clinical experience;Fletcher;J. R. Soc. Med.,1978

5. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man;Freireich;Cancer Chemother. Rep.,1966

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring Greater Flexibility for Chronic Toxicity Study Designs to Support Human Safety Assessment While Balancing 3Rs Considerations;International Journal of Toxicology;2024-05-31

2. Translation of nonclinical to clinical safety findings for 27 biotherapeutics;Toxicology and Applied Pharmacology;2024-03

3. Poor Translatability of Biomedical Research Using Animals — A Narrative Review;Alternatives to Laboratory Animals;2023-03

4. Future of Regulatory Safety Assessment;Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays;2023

5. Role of human epidemiology in risk assessment and management;Present Knowledge in Food Safety;2023